The effect of glycaemic control on fibrin network structure of type 2 diabetic subjects.
Diabetic subjects have been shown to have altered fibrin network structures. One possible cause may be fibrinogen glycation resulting in altered structure/function properties. We investigated the effect of glucose control on fibrinogen glycation and fibrin network structure in type 2 diabetes. Blood samples were taken from twenty uncontrolled diabetic subjects at baseline to determine the levels of fibrinogen glycation and fibrin network structures. The subjects were then treated with insulin until blood glucose control was achieved before end blood samples were taken. Twenty age- and BMI-matched non-diabetic subjects were included as a reference group. The diabetic subjects had significantly higher mean fibrinogen glycation at baseline than the non-diabetic subjects (7.84 vs. 3.89 mol glucose / mol fibrinogen; p < 0.001). This was significantly reduced during the intervention (7.84 to 5.24 mol glucose / mol fibrinogen; p < 0.0002) in the diabetic group. Both groups had high mean fibrinogen concentrations (4.25 and 4.02 g/l, diabetic and non-diabetic subjects respectively). There was no difference in fibrinogen concentration, porosity, compaction and kinetics of clot formation between the diabetic subjects and non-diabetic subjects at baseline, nor were there any changes during the intervention despite the reduced fibrinogen glycation. Fibrin network characteristics correlated well with fibrinogen but not with any markers of glycaemic control. Improved glycaemic control resulted in decreased fibrinogen glycation but not fibrinogen concentration. It seems as though porosity, compaction and kinetics of clot formation are more related to fibrinogen concentration than fibrinogen glycation in this model.
Pieters
Marlien
M
Department of Nutrition, North-West University, Potchefstroom Campus, Private Bag X6001, Potchefstroom, 2520 South Africa. vgemp@puk.ac.za
Covic
Namukolo
N
Loots
Du Toit
du T
van der Westhuizen
Francois H
FH
van Zyl
Danie G
DG
Rheeder
Paul
P
Jerling
Johann C
JC
Weisel
John W
JW
D000328:Adult; D000368:Aged; D001777:Blood Coagulation; D001786:Blood Glucose / Q000032:analysis / Q000502:physiology*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D005260:Female; D005337:Fibrin / Q000737:chemistry / Q000648:ultrastructure*; D005340:Fibrinogen / Q000031:analogs & derivatives / Q000032:analysis / Q000378:metabolism*; D006031:Glycosylation; D006801:Humans; D007328:Insulin / Q000008:administration & dosage* / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D016062:Porosity; D006023:Glycoproteins
D001786:Blood Glucose; D005337:Fibrin; D005340:Fibrinogen; D007328:Insulin; C044548:glycosylated fibrinogen; D006023:Glycoproteins